2020
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up JACC State-of-the-Art Review
Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, Der Nigoghossian C, Ageno W, Madjid M, Guo Y, Tang LV, Hu Y, Giri J, Cushman M, Quéré I, Dimakakos EP, Gibson CM, Lippi G, Favaloro EJ, Fareed J, Caprini JA, Tafur AJ, Burton JR, Francese DP, Wang EY, Falanga A, McLintock C, Hunt BJ, Spyropoulos AC, Barnes GD, Eikelboom JW, Weinberg I, Schulman S, Carrier M, Piazza G, Beckman JA, Steg PG, Stone GW, Rosenkranz S, Goldhaber SZ, Parikh SA, Monreal M, Krumholz HM, Konstantinides SV, Weitz JI, Lip GYH, Global COVID-19 Thrombosis Collaborative Group E. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up JACC State-of-the-Art Review. Journal Of The American College Of Cardiology 2020, 75: 2950-2973. PMID: 32311448, PMCID: PMC7164881, DOI: 10.1016/j.jacc.2020.04.031.Peer-Reviewed Original ResearchConceptsAntithrombotic therapyThrombotic diseaseCOVID-19Outcomes of patientsViral respiratory illnessEndothelial dysfunctionArterial thrombosisThromboembolic diseaseExcessive inflammationRespiratory illnessLaboratory monitoringJACC StateArterial circulationPlatelet activationPatientsCoronavirus diseaseDiseaseTherapyCOVID-19 pandemicPreventionCurrent understandingThromboticThrombosisInflammationDysfunction
2009
Increased Mortality among Survivors of Myocardial Infarction with Kidney Dysfunction: the Contribution of Gaps in the use of Guideline-Based Therapies
Peterson PN, Ambardekar AV, Jones PG, Krumholz HM, Schelbert E, Spertus JA, Rumsfeld JS, Masoudi FA. Increased Mortality among Survivors of Myocardial Infarction with Kidney Dysfunction: the Contribution of Gaps in the use of Guideline-Based Therapies. BMC Cardiovascular Disorders 2009, 9: 29. PMID: 19586550, PMCID: PMC2716301, DOI: 10.1186/1471-2261-9-29.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedFemaleGlomerular Filtration RateHumansKaplan-Meier EstimateKidney DiseasesMaleMiddle AgedMyocardial InfarctionPractice Guidelines as TopicProportional Hazards ModelsProspective StudiesRegistriesRisk AssessmentSeverity of Illness IndexSurvivorsTime FactorsTreatment OutcomeUnited StatesConceptsGlomerular filtration rateAcute myocardial infarctionGuideline-based medical therapyGuideline-based therapyMedical therapyKidney dysfunctionMyocardial infarctionUse of guidelinesEligible patientsRenal dysfunctionHazard ratioCox regressionPathophysiological abnormalitiesClinical variablesKidney diseaseFiltration rateNovel therapiesUS CentersHigh mortalityPatientsTherapyFurther adjustmentMortalityDysfunctionTreatment factors
2004
838-1 National patterns of spironolactone prescription for older patients with heart failure and left ventricular systolic dysfunction before and after RALES
Masoudi F, Gross C, Wang Y, Havranek E, Rathore S, Foody J, Krumholz H. 838-1 National patterns of spironolactone prescription for older patients with heart failure and left ventricular systolic dysfunction before and after RALES. Journal Of The American College Of Cardiology 2004, 43: a415. DOI: 10.1016/s0735-1097(04)91750-0.Peer-Reviewed Original Research
2003
The effectiveness of angiotensin converting enzyme inhibitors in medicare beneficiaries with heart failure and left ventricular systolic dysfunction: results of the National Heart Care Project
Masoudi F, Rathore S, Wang Y, Havranek E, Foody J, Krumholz H. The effectiveness of angiotensin converting enzyme inhibitors in medicare beneficiaries with heart failure and left ventricular systolic dysfunction: results of the National Heart Care Project. Journal Of Cardiac Failure 2003, 9: s86. DOI: 10.1016/s1071-9164(03)00163-5.Peer-Reviewed Original ResearchReview: Beta-blockers increase fatigue and sexual dysfunction but not depression after myocardial infarction.
Ko DT, Hebert PR, Krumholz HM. Review: Beta-blockers increase fatigue and sexual dysfunction but not depression after myocardial infarction. Annals Of Internal Medicine 2003, 138: 30; author reply 30. PMID: 12511138, DOI: 10.7326/acpjc-2003-138-1-030.Peer-Reviewed Original Research
2002
Clinical trials do not support strong association of beta-blocker therapy with fatigue, depression, or sexual dysfunction
Ko D, Hebert P, Coffey C, Sedrakyan A, Curtis J, Krumholz H. Clinical trials do not support strong association of beta-blocker therapy with fatigue, depression, or sexual dysfunction. Journal Of The American College Of Cardiology 2002, 39: 440. DOI: 10.1016/s0735-1097(02)81978-7.Peer-Reviewed Original Researchβ-Blockers in Heart Failure: Clinical Applications
Farrell MH, Foody JM, Krumholz HM. β-Blockers in Heart Failure: Clinical Applications. JAMA 2002, 287: 890-897. PMID: 11851583, DOI: 10.1001/jama.287.7.890.Peer-Reviewed Original ResearchConceptsHeart failureLeft ventricular systolic dysfunctionVentricular systolic dysfunctionHeart failure patientsQuality of careSeries of casesSystolic dysfunctionFailure patientsPatient selectionConsensus guidelinesFluid statusΒ-blockersPatientsScientific evidenceClinical applicationCareGuidelinesSafetyMorbidityFailureDysfunctionTherapyMortality